Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Clinical trial NCT06797635 · RECRUITING
Trial details
- NCT number
- NCT06797635
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-03-20
- Primary completion
- 2029-12-31
- Enrollment
- 372
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.